Microangiopathic hemolytic anemia overview

Microangiopathic hemolytic anemia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Microangiopathic hemolytic anemia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Microangiopathic hemolytic anemia overview On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Microangiopathic hemolytic anemia overview All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Microangiopathic hemolytic anemia overview
on Microangiopathic hemolytic anemia overview
Microangiopathic hemolytic anemia overview in the news
Blogs on Microangiopathic hemolytic anemia overview
Directions to Hospitals Treating Microangiopathic hemolytic anemia
Risk calculators and risk factors for Microangiopathic hemolytic anemia overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

In medicine (hematology) microangiopathic hemolytic anemia (MAHA) is a subgroup of hemolytic anemia (anemia, loss of red blood cells through destruction) caused by factors in the small blood vessels. It is identified by the finding of anemia and schistocytes onmicroscopy of the blood film.